Bounce (defined as an increase > 0.2 ng/mL) following ultra hypofrac #radiotherapy, is frequent (36%) & associated with improved prognosis. Data from HYPO RT PC at #ESTRO25 Possible bias (bounces by definition have a decrease in PSA after the rise) role of 3y landmark analysis

EMBRACE II results Improving outcomes for Cervix cancer patients Overall Survival +3y: 87% 5y: 82% Disease-Specific Survival +3y: 89% 5y: 85% Progression-Free Survival +3y: 78% 5y: 73% #ESTRO25

STAR-TREC: CRT vs. SC RT (5x5 Gy) for organ preservation in early/intermediate RC PRIME-RT: Durvalumab plus extended TNT in locally advanced RC STELLAR: SC RT + chemo vs. CRT for advanced RC STELLAR II: SC RT + chemo+ sintilimab in pMMR/MSS RC #ESTRO25 #rectalcancer

Dr. Lucia Viola on IASLC Nomination, Expanding Screening Access, and AI ... youtu.be/sPzi0XZCZhc?si… via YouTube Many thanks to OncoDaily for the opportunity to share my thoughts!

Fantastic Grey Zone topic for June of 2025 Which Way to (INDI)GO? Case: 42 yo male with STR of a WHO grade 2 IDH mutant (IDH1 R132H) astrocytoma with loss of ATRX, no 1p/19q codeletion, and no homozygous deletion of CDKN2A/B. redjournal.org/article/S0360-… IJROBP - The Red Journal

🚨 Randomized Trial: Significantly less symptom burden with SRS compared to HA-WBRT. SRS Standard of Care for 5-20 brain mets 🚨🚨🚨

DOTATATE PET/MR represents a promising #ImagingBiomarker for response assessment in #meningiomas treated with #radiosurgery - this was the important finding from a recent study. Read about it now in #NeuroOncology: academic.oup.com/neuro-oncology…

X-torial: Cleaning up the misinformation about Joe Biden and #ProstateCancer that I am reading everywhere. The purpose of this is to provide education from someone who treats and studies PCa for a living, lead the USA National Comprehensive Cancer Network (NCCN) PCa guidelines, hold leadership in NRG Oncology National Cancer Institute

Gr2 Mening SRS Margin Dose and Local Control · SRS >14 better LC if high Ki-67 · ↑↑dose NO benefit for low Ki-67 · Pred ↓↓LC high Ki-67, <14 Gy, large size, convexity journals.lww.com/neurosurgery/a…

For select breast cancer patients with complete response to neoadjuvant systemic therapy, radiotherapy alone without breast surgery may be feasible, as no tumor recurrences were observed at 5-year follow-up. ja.ma/4jxfdEA

It’s a great analysis. As someone not as familiar w censoring - appreciate your app & explaining, and I think what you’ve said re: possibility of informed censoring is convincing. Hopefully you can get the data. While I am also a huge believer in limiting time toxicity/cost/side

In this month's Radiotherapy & Oncology Van Aken, et al describe a framework to assess interactions and safety of targeted therapes or #Immunotherapy combinations with #Radiotherapy ➡️Pragmatic and biologically informed guidance on how to address 🔗doi.org/10.1016/j.rado…

☢️Preoperative vs Postoperative SRT for brain metastases❓ ✅time between surgery and radiation therapy was shorter ✅safe and logistically feasible 👉jamanetwork.com/journals/jamao… #cancer #oncology #MedX OncoAlert M. Bolton Dr. Nina Niu Sanford Jeff Ryckman

Happy to introduce something different from classical curative or palliative radiotherapy: Strategic radiotherapy: a new proof of concept sciencedirect.com/science/articl… ESTRO Sapienza Università di Roma

I learned this week that SABR-COMET patient #1 recently passed away, more than 12 years after enrollment, with no recurrence since his original SABR. We initially treated him for a left adrenal met. It’s an interesting story… ⬇️⬇️⬇️

🚨ACCORD Trial🚨 Resected Extrahepatic CCA or Gallbladder CA 🔍Randomized Adjuvant CRT + Camrelizumab vs Observation 🔥Whopping improvement in OS and RFS with CRT + ICI with persistent separate at tail of the curve!!! tinyurl.com/64yc3uum JAMA Oncology

❗️ Important work for SCLC 1-10 brain mets -> SRS mOS 10.2 m Only 22% of patients needed salvage WBRT Median 2 brain mets ascopubs.org/doi/10.1200/JC…

Phase 2 SRS Small Cell Lung CA 1-10 Brain Mets · 100 patients Median # brain met 2 · Median OS 10 mos · 1 Yr LC 85% · 1 Yr Distant Brain Control 41% ascopubs.org/doi/10.1200/JC…

Definition of resectable stage III NSCLC: Systematic review (n=70) Only 58% defined “resectable”; 60% excluded N3, 32% multistation N2. 🧮 Proposed: single-station N2, R0 feasible, MDT consensus. lungcancerjournal.info/article/S0169-… OncoAlert

Does the addition of MDT to standard of care continuous ADT improve outcomes for oligomet prostate ca? Happy to share the results of EXTEND evaluating this question alongside PI Chad Tang, MD & many others